ArticleFolia microbiologica2026
Multifunctional biotherapeutic probiotic bacteria with antioxidant capacity for cholesterol reduction, and inflammation alleviation.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to isolate, characterize, and evaluate novel lactic acid bacteria (LAB) from local dairy products for their multifunctional probiotic potential, with a focus on cholesterol-lowering, antioxidant, and anti-inflammatory properties. A total of 24 raw milk and yogurt samples were collected, from which ten isolates were selected. In vitro assessment revealed significant cholesterol assimilation capacities ranging from 18.26% to 38.05%, with isolates NNY and HEY exhibiting the highest activity. These strains also demonstrated strong bile salt hydrolase (BSH) activity, high tolerance to simulated gastrointestinal conditions, resistance to phenol, broad-spectrum antimicrobial activity against foodborne pathogens, and favorable antibiotic susceptibility profiles. Both strains adhered effectively to Caco-2 cells and exhibited notable antioxidant (DPPH scavenging) and anti-inflammatory (albumin denaturation inhibition) activities. Scanning electron microscopy revealed distinct surface morphological changes supporting surface association of cholesterol with the bacterial cells. When applied in a high-fat cream matrix, the combined culture of HEY and NNY reduced cholesterol content by 11.4%, as validated by HPLC. Molecular identification via 16 S rRNA sequencing identified HEY as Lacticaseibacillus paracasei and NNY as Lacticaseibacillus chiayiensis. These findings highlight the potential of these indigenous LAB strains as multifunctional probiotics for cholesterol management and functional food development.
Indexed as
Identifiers
42008077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.